Effects on re-endothelialisation with Bydureon treatment add on to Insulin versus Insulin alone, both in combination with Metformin in type 2 diabetic subjects (Rebuild Study).

Trial Profile

Effects on re-endothelialisation with Bydureon treatment add on to Insulin versus Insulin alone, both in combination with Metformin in type 2 diabetic subjects (Rebuild Study).

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Exenatide (Primary) ; Exenatide (Primary) ; Insulin aspart; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms Rebuild
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Aug 2016 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
    • 31 Aug 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top